Cardiomyocyte apoptosis serves an important role in diabetic cardiomyopathy. Liraglutide, a
glucagon-like peptide-1 analog, has been indicated to exert a cardioprotective effect …

In type 2 diabetes, lipotoxicity damages islet microvascular endothelial cells (IMECs),
leading to pancreatic islet β cell dysfunction directly or indirectly. Glucagon-like peptide-1 …

Abstract Glucagon-like peptide-1 receptor (GLP-1R) agonists improve cardiovascular
dysfunction via the pleiotropic effects behind their receptor action. However, it is unknown …

OBJECTIVE Glucagon-like peptide-1 receptor (GLP-1R) agonists are used to treat type 2
diabetes, and transient GLP-1 administration improved cardiac function in humans after …

The primary aim of the present study was to evaluate the effects of liraglutide on
glucolipotoxicity‑induced liver cell apoptosis and the underlying mechanisms in Zucker …

In recent years, the interest towards the relationship between incretins and bone has been
increasing. Previous studies have suggested that glucagon-like peptide-1 (GLP-1) and its …

Recent studies have underscored the cardioprotective properties of liraglutide. This
research explores its impact on cardiac hypertrophy and heart failure following transverse …

Liraglutide has been extensively applied in the treatment of type 2 diabetes mellitus and
also has hepatoprotective effects. However, the role of liraglutide treatment on liver injury in …

OBJECTIVE: To study the effect and mechanism of liraglutide on the apoptosis of human
hepatocellular carcinoma HepG2 cells. MATERIALS AND METHODS: HepG2 cell was …

Diabetic cardiomyopathy is an important contributor to morbidity and mortality of diabetic
patients by causing heart failure. Interstitial and perivascular fibrosis plays a crucial role in …